Lars Johannesen

机构：United States Food and Drug Administration, Center for Drug Evaluation and Research

发表论文 85 篇 · 总被引 2665 次 · h-index 23

代表论文

• An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel (2016 · Journal of Pharmacological and Toxicological Methods · 被引 304)
• Comprehensive Translational Assessment of Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias (2016 · Toxicological Sciences · 被引 283)
• Mechanistic Model‐Informed Proarrhythmic Risk Assessment of Drugs: Review of the “CiPA” Initiative and Design of a Prospective Clinical Validation Study (2017 · Clinical Pharmacology & Therapeutics · 被引 135)
• Common Genetic Variant Risk Score Is Associated With Drug-Induced QT Prolongation and Torsade de Pointes Risk (2017 · Circulation · 被引 126)
• Assessment of Multi‐Ion Channel Block in a Phase I Randomized Study Design: Results of the Ci PA Phase I ECG Biomarker Validation Study (2018 · Clinical Pharmacology & Therapeutics · 被引 95)
• Electrocardiographic Biomarkers for Detection of Drug-Induced Late Sodium Current Block (2016 · PLoS ONE · 被引 37)